Zafgen Культура компании

Mr. Thomas E. Hughes, also known as Tom, Ph.D., has been the President and Chief Science Officer of ZafGen, Inc. since July 2016 and October 10, 2017 respectively. Mr. Hughes is an Atlas Advisor at Atlas Venture L.P. He served as the Chief Executive Officer of ZafGen, Inc. since October 2008 to October 10, 2017. He is a part of Life Sciences group. He was Entrepreneur-in-Residence and Venture Partner. He served as President of ZafGen, Inc. since October 2008 until June 2014. He has held Adjunct Professorships in Molecular Genetics and Biochemistry at the School of Medicine and Dentistry of the State of New Jersey and at Tufts University School of Medicine. During his 20-year tenure at Novartis, he served as a Vice President and Global Head of the Cardiovascular and Metabolism Disease Area. He served as the Site Head for research at Novartis' research facility. He also served as Global Head of Diabetes Research at Novartis, where he directed drug discovery research teams specializing in type 2 diabetes and metabolic disorders. From 1987 to 2008, Mr. Hughes held several positions at Novartis AG including Vice President and Global Head of the Cardiovascular and Metabolic Diseases Therapeutic Area at the Novartis Institutes for BioMedical Research in Cambridge MA. From 1995 to 2001, he led discovery efforts at Novartis that resulted in the validation of DPP-4 inhibition as a therapeutic approach to type 2 diabetes, as well as the identification and advancement of vildagliptin. He serves as a Member of Scientific Advisory Board at Nimbus Therapeutics, Inc. and Nimbus Discovery, LLC. He has been a Director of ZafGen, Inc. since 2008 and miRagen Therapeutics, Inc. since September 24, 2009. He serves as a Member of Scientific Advisory Board at Navitor Pharmaceuticals, Inc. and Nimbus Discovery, LLC. He serves as a Member of Strategic Advisory Board of Broadview Ventures, Inc. Mr. Hughes has been involved in numerous drug discovery efforts in the metabolic and cardiovascular disease area, focusing on glucose homeostasis, lipid metabolism and the control of blood clotting. He has more than 20 years of drug discovery and development experience. He has more than 25 years of experience in the biomedical and pharmaceutical research and development. He has authored over 40 peer-reviewed publications and is an inventor on numerous issued and pending patents related to the treatment of diabetes, cardiovascular disease and obesity. In 2007, R&D Directions magazine named him one of the 20 Most Notable People in R&D. Mr. Hughes earned his Ph.D. in Nutrition from Tufts University and received an M.S. in Zoology from Virginia Polytechnic Institute & State University. He graduated with a B.A. in Biology from Franklin and Marshall College.

Dr. Dennis D. Kim, M.D., MBA, has been Consulting Chief Medical Officer at Diamedica Inc. since April 2013. Dr. Kim is a Founding Member/Principal of MetaCon, Inc. He has been the Chief Medical Officer of Zafgen, Inc. since September 2011. Dr. Kim served as Consulting Chief Medical Officer at Cebix Incorporated. He is an Endocrinologist by training and has a unique skill set of clinical, regulatory and business development experience in the fields of obesity, endocrinology, diabetes and metabolism. He is a board-certified Endocrinologist and has more than 10 years of experience in the biotech and medical technology industries. Prior to Zafgen, he served multiple senior-level clinical and corporate affairs positions at Orexigen Therapeutics Inc., a biopharmaceutical company focused on the treatment of obesity, including Senior Vice President and Head of Obesity/Metabolic Diseases from September 25, 2008 to January 2009 and Senior Vice President of Corporate Development and Senior Vice President of Medical Affairs and Communications since January 2009. He joined Orexigen Therapeutics, Inc. from EnteroMedics, Inc. He served as the Chief Medical Officer and Vice President of Medical Affairs at EnteroMedics, Inc. from August 24, 2007 to September 18, 2008. He served at Amylin Pharmaceuticals, where he served as an Executive Director of Corporate Strategy. He is a Clinical Assistant Professor of Medicine at UCSD. He is a Board-certified endocrinologist. Dr. Kim holds an M.D. from the Chicago Medical School. He completed his internal medicine residency at Rush Presbyterian St. Luke's Medical Center and an endocrinology fellowship at the University of California, San Diego (USCD) School of Medicine. Dr. Kim also holds a Master of Business Administration degree in Biotech Structure and Strategy from UCSD's Rady School of Business. He holds a B.S. in Biology from UCLA.

Dr. James E. Vath, Ph.D. has been Head of Research and Development at Zafgen, Inc. since 2006 and serves as its Head of Discovery and Development. Dr. Vath joined Zafgen in 2006 and has over 19 years of experience in the biotechnology and pharmaceutical industries to his role as head of discovery and development. Prior to joining Zafgen, Dr. Vath worked with established companies and new ventures to assess, develop and execute product development plans. As senior vice president of product development at Phylogix Inc., Dr. Vath created and implemented the corporate operational and R&D plan for the lead product in oncology-supportive care. Prior to Phylogix, he served as Senior Vice President of Research at Praecis Pharmaceuticals since March 2002 where he led the R&D organization through multiple IND filings and a product approval. Dr. Vath served as Vice President of Preclinical Research of Praecis Pharmaceuticals Inc. from January 2001 to March 2002 and from July 1999 to January 2001, served as Vice President of Analytical Chemistry. Prior to joining Praecis, from 1996 to 1999, Dr. Vath was employed by Millenium Pharmaceuticals, Inc., a biotechnology company, as Director of Proteomics and Protein Technologies from 1998 to 1999 and from 1996 to 1998 as a Senior Scientist. From 1994 to 1996, Dr. Vath served as Lab Head and Principal Scientist for Genetics Institute, Inc., a biotechnology company and from 1989 to 1994 served Genetics Institute as a Staff Scientist. Dr. Vath is a contributing author on numerous peer-reviewed journal publications and book chapters. Dr. Vath received his B.S. in Chemistry from Northeastern University and his Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology.

Patricia Allen serves as the Chief Financial Officer of Zafgen, Inc.. Patricia started at Zafgen, Inc. in Jan of 2013. Patricia currently resides in the Greater Boston Area.

Dennis Kim serves as the Chief Medical Officer of Zafgen, Inc.. Dennis started at Zafgen, Inc. in Sep of 2011. Dennis currently resides in the Greater San Diego Area.

Brian McVeigh serves as the Chief Business Officer of Zafgen, Inc.. Brian started at Zafgen, Inc. in May of 2018. Brian currently resides in the Greater Philadelphia Area.

Erin Brubaker serves as the VP Commercial Strategy and Business Development of Zafgen, Inc.. Erin started at Zafgen, Inc. in August of 2018. Erin currently resides in the Greater Philadelphia Area.

Thomas Daniel serves as the Director of Zafgen, Inc.. Thomas started at Zafgen, Inc. in March of 2016. Thomas currently resides in the Greater San Diego Area.